AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02980965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel
Description: Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.
Study NCT02980965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil, epirubicin, cyclophosphamide, docetaxel
Description: Patients received fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.
Study NCT04460222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotational Thromboelastometry to guide blood product transfusion pre invasive procedure
Description: Rotational Thromboelastometry will be performed pre procedure and blood component will be transfused if~* EXTEM CT more than 80 sec then FFP will be transfused at 15 ml/kg MCF less than 35 mm then Platelet will be transfused at 10 ml/kg~* FIBTEM MCF less than 7 mm then Cryoprecipitate will be transfused at 5 ml/kg
Study NCT04460222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional transfusion methods to guide blood product transfusion pre invasive procedure
Description: Transfusion will be given If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg
Study NCT00152217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 (S-1)
Description: 80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
Study NCT00152217 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
Study NCT02690675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron fortified formula milk
Description: One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.
Study NCT04168177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: Patient controlled analgesia
Study NCT04168177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP
Description: erector spinae plane block
Study NCT02481895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-neurocognitive module
Description: The experimental group will take part of a 12-week extension with a total of 36 hours training with the e-neurocognitive module tailored for bipolar patients
Study NCT02829749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoChord beating heart mitral valve implantation
Description: The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
Study NCT02276456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up Appointment- early vs standard
Description: Patient will undergo early follow-up (within 7 days of discharge) of discharge
Study NCT04314453 — intervention group
Intervention type: OTHER
Intervention: percutaneous endoscopic lumbar discectomy
Description: Resection of the hypertrophied faceted joints, osteophyte formation and ligamentum flavum (LF) hypertrophy, with or without disc protrusion for degenerative spinal stenosis.
Study NCT00103740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 5 mg zoledronic acid in 5 mL of sterile water for infusion
Study NCT00103740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to zoledronic acid
Description: 5 mL of sterile water for infusion
Study NCT02451553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Dimaleate
Description: Given PO
Study NCT02451553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT02451553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02060071 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: Blood test
Study NCT01596894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin + Metronidazole
Description: Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
Study NCT01596894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
Study NCT03686917 — intervention group
Intervention type: OTHER
Intervention: CHAT-P
Description: Survey
Study NCT00103740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 30mg oral tablets overencapsulated to match the placebo capsules
Study NCT00103740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to risedronate
Description: oral capsules
Study NCT00103740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and vitamin D supplements
Description: Calcium and vitamin D supplements were supplied
Study NCT03722602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation after stroke
Description: The program of the rehabilitation was designed specifically for each patient. It was prepared to match the patient's functional status and the defined goals. The subjects participated in exercise five days per week, for five weeks. During their stay at the Clinic, the patients took part in morning exercise and received individual practice, based on neuro-developmental treatment (Bobath concept), and proprioceptive neuromuscular facilitation (PNF) method, addressing the impaired motor abilities; if it was needed they also performed exercise based on equipment using biological feedback: Balance Trainer (static and dynamic parapodium) and Pablo system designed for upper limb training.
Study NCT00872404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: 20mg/kg/3 weeks
Study NCT04796142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medication reconciliation
Description: medication reconciliation
Study NCT01445379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
Study NCT03574649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study NCT03574649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study NCT03574649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)
Study NCT03574649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)
Study NCT03574649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03574649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03574649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
Study NCT03574649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine
Study NCT03574649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
Study NCT03574649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: RAS yeast vaccine
Study NCT03574649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine
Study NCT03574649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin
Description: INNO-206
Study NCT03574649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
Study NCT03574649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
Study NCT03574649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
Study NCT03574649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel
Study NCT03574649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: carboplatin
Study NCT00282009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Internet
Description: Basic Internet control intervention
Study NCT00282009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Internet
Description: enhanced Internet cessation intervention
Study NCT00282009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Internet + phone
Description: enhanced Internet plus proactive telephone counseling
Study NCT02122822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp96
Description: vaccination of autologous gp96 derived from tumor tissue + basal treatment
Study NCT00762853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush half mouth once with assigned study treatment
Study NCT00762853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride and triclosan
Description: Brush half mouth once with assigned study treatment
Study NCT02973789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T
Description: Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.~Other Name: TTFields~Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
Study NCT02973789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immune checkpoint inhibitors or docetaxel
Description: Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
Study NCT03795792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Will be provided in capsules
Study NCT03795792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hydrolyzed collagen
Description: Will be provided in capsules.
Study NCT01196741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
Study NCT01196741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
Study NCT01196741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saracatinib
Description: Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
Study NCT01196741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
Study NCT01998334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CVVH 6h
Description: CVVH 6h for first three days
Study NCT01998334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CVVH 10h
Description: CVVH 10h for first three days
Study NCT01998334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CVVHDF 6h
Description: CVVHDF 6h for first three days
Study NCT01596777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loperamide
Description: 20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
Study NCT01596777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: 20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
Study NCT02973789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors or docetaxel
Description: Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
Study NCT04408625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3884963
Description: Participants will receive a single dose of LY3884963, administered intra cisterna magna
Study NCT01596777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loperamide placebo
Description: 200 ml apple juice
Study NCT01596777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylnaltrexone placebo
Description: Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
Study NCT01596777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone 12 mg sc.
Description: RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
Study NCT01596777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone IR capsule
Description: Methylnaltrexone bromide 500 mg IR capsule
Study NCT01596777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone ER capsule
Description: Methylnaltrexone bromide 500 mg ER capsule
Study NCT01596777 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Colon Transit
Description: 3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
Study NCT01596777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colon Transit
Description: 3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
Study NCT01596777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfasalazine
Description: 500 mg Azulfidine® (Pharmacia)
Study NCT01596777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: 500 mg Azulfidine® (Pharmacia)
Study NCT03029689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
Study NCT03029689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
Study NCT03029689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Current ART
Description: 3-drug antiretroviral treatment including PI/r/c or NNRTI
Study NCT03029689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Current ART
Description: 3-drug antiretroviral treatment including PI/r/c or NNRTI
Study NCT02817685 — intervention group
Intervention type: OTHER
Intervention: 3 months
Study NCT02817685 — intervention group
Intervention type: OTHER
Intervention: 6 months
Study NCT02817685 — intervention group
Intervention type: OTHER
Intervention: 3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI
Study NCT03819647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stiripentol (Diacomit)
Description: Administration of stiripentol per os
Study NCT04677985 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Menthol based topical analgesic
Description: Topical analgesic or placebo was applied to upper and lower body muscles and tendons and pain pressure threshold was measured with a handheld algometer.
Study NCT04677985 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Menthol based topical analgesic
Description: Topical analgesic or placebo was applied to upper and lower body muscles and tendons and pain pressure threshold was measured with a handheld algometer.
Study NCT04408625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV pulses every 2 weeks in the first 3 months.
Study NCT04408625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional Sirolimus
Description: At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
Study NCT04408625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optional Prednisone
Description: If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen
Study NCT02876185 — intervention group
Intervention type: OTHER
Intervention: Monitoring by an orthoptist then by an ophthalmologist
Description: At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
Study NCT00570492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray
Description: Fluticasone furoate nasal spray 110mg QD
Study NCT02392481 — intervention group
Intervention type: PROCEDURE
Intervention: Biofluid sampling
Study NCT02385474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12% SDF
Description: 12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure
Study NCT02385474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% SDF
Description: 38% silver diamine fluoride solution, of which the capability of arresting dental caries is known
Study NCT03334513 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: intravitreal injection of bevacizumab
Study NCT03334513 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab
Description: intravitreal injection of ranibizumab
Study NCT01110018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK573719 (SOLUTION)
Description: 20μg /mL solution for IV and Oral dosing
Study NCT00103740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplements
Description: Calcium and vitamin D supplements were supplied
Study NCT01288001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ostenil plus
Description: 2% Sodium Hyaluronate plus Mannitol injection
Study NCT00519051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)
Description: Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
Study NCT03419988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: 24 sessions of aerobic exercise
Study NCT00880295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic carpal tunnel release
Description: endoscopic surgery, which is standard of care for carpal tunnel release